QuickView for TAKL;jsessionid=40E22499564EAE7F71FA29AA19705F76;jsessionid=787005E39F3AFF5E382EC41A340AB170;jsessionid=C367D95CAF574A9239FE4295078310FA;jsessionid=DF855E1FCDC082CA178D4759DE591992;jsessionid=CEC07D6E3BD976C0A49BA3484965CE27;jsessionid=CC2B2FF77BE70ED30A59008DC57D82D7;jsessionid=BCDCBA568148BCE772D8C18BD107F409;jsessionid=87BCD66CB73E0442B3535617CE520F90;jsessionid=0A20B89A448ED198031CACF8505CE4CB;jsessionid=0ED8E6B5C914D11C93ED8BD3B1E4DE8E;jsessionid=1B3C68DDD76ED989FFB75C59B081C88C;jsessionid=91D87191ACD3608CF353615032D44387 (gene)

1. Computational analysis predicts the Kaposi's sarcoma-associated herpesvirus tegument protein ORF63 t…
2. Disruption of Prostaglandin E2 Signaling in Cancer-Associated Fibroblasts Limits Mammary Carcinoma G…
3. Stability of varicella-zoster virus open reading frame 63.
4. Varicella-zoster virus ORF63 inhibits apoptosis of primary human neurons.
5. Regions of the varicella-zoster virus open reading frame 63 latency-associated protein important for…

There were no clinical trials for TAKL;jsessionid=40E22499564EAE7F71FA29AA19705F76;jsessionid=787005E39F3AFF5E382EC41A340AB170;jsessionid=C367D95CAF574A9239FE4295078310FA;jsessionid=DF855E1FCDC082CA178D4759DE591992;jsessionid=CEC07D6E3BD976C0A49BA3484965CE27;jsessionid=CC2B2FF77BE70ED30A59008DC57D82D7;jsessionid=BCDCBA568148BCE772D8C18BD107F409;jsessionid=87BCD66CB73E0442B3535617CE520F90;jsessionid=0A20B89A448ED198031CACF8505CE4CB;jsessionid=0ED8E6B5C914D11C93ED8BD3B1E4DE8E;jsessionid=1B3C68DDD76ED989FFB75C59B081C88C;jsessionid=91D87191ACD3608CF353615032D44387